Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors

British Journal of Pharmacology

Volumn 153, Issue 1, 2008, Pages 6-20

  Negre Salvayre, A ^a,b   Coatrieux, C ^a   Ingueneau, C ^a   Salvayre, R ^a  

^a INSERM   (France)

^b CHU RANGUEIL   (France)

Author keywords

4 hydroxynonenal; ALE; Atherosclerosis; Cancer; Carbonyl scavenger; Carbonyl stress; Diabetes; Inflammation; Lipid peroxidation; Neurodegenerative diseases

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 6,7,8,9 TETRAHYDRO 9 (2 MORPHOLINOETHYL) 2,4 BIS(1 PYRROLIDINYL) 5H PYRIMIDO[4,5 B]INDOLE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIOXIDANT; CANDESARTAN; CAPTOPRIL; CARNOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HISTIDINE DERIVATIVE; HYDRALAZINE; HYDRAZINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; POLYPHENOL DERIVATIVE; PROTEASOME; PROTEIN KINASE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; PYRIDOXAMINE; PYRIDOXINE; PYRROLIDINE DITHIOCARBAMATE; RESVERATROL; S ADENOSYLMETHIONINE; SCAVENGER; TYROSINE KINASE RECEPTOR;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CELL CYCLE; DEGENERATIVE DISEASE; HUMAN; INFLAMMATORY DISEASE; LIPID PEROXIDATION; NEOPLASM; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN MODIFICATION; PYRIDOXINE DEFICIENCY; REVIEW; SIGNAL TRANSDUCTION;

AGING; ALDEHYDES; ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CELL CYCLE; HUMANS; INFLAMMATION; LIPID PEROXIDATION; LIPOPROTEINS, LDL; NEOPLASMS; NEURODEGENERATIVE DISEASES; NF-KAPPA B; OXIDATION-REDUCTION; PROTEINS; SIGNAL TRANSDUCTION;

EID: 37849013375     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707395     Document Type: Review

References (179)

1. Aldini G, Dalle-Donne I, Colombo R, Maffei Facino R, Milzani A, Carini M (2006). Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. Chem Med Chem 1: 1045-1058.
2. Almolki A, Taille C, Martin GF, Jose PJ, Zedda C, Conti M et al. (2004). Heme oxygenase attenuates allergen-induced airway inflammation and hyperreactivity in guinea pigs. Am J Physiol Lung Cell Mol Physiol 287: L26-L34.
3. Altuntas Y, Guven M, Ince E, Acbay O, Caner M, Kanigur-Sultuybek G (1995). The in vitro effects of captopril on the levels of lipid peroxidation and glutathione of erythrocytes in type II diabetes. J Basic Clin Physiol Pharmacol 6: 281-288.
4. Andreoletti O, Levavasseur E, Uro-Coste E, Tabouret G, Sarradin P, Delisle MB et al. (2002). Astrocytes accumulate 4-hydroxynonenal adducts in murine scrapie and human Creutzfeldt-Jakob disease. Neurobiol Dis 11: 386-393.
5. Anekonda TS (2006). Resveratrol - a boon for treating Alzheimer's disease? Brain Res Rev 52: 316-326.
6. Arakawa M, Ishimura A, Arai Y, Kawabe K, Suzuki S, Ishige K et al. (2006). N-Acetylcysteine and ebselen but not nifedipine protected cerebellar granule neurons against 4-hydroxynonenal-induced neuronal death. Neurosci Res 57: 220-229.
7. Awasthi YC, Yang Y, Tiwari NK, Patrick B, Sharma A, Li J et al. (2004). Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. Free Rad Biol Med 37: 607-619.
8. Bardell AL, MacLeod KM (2001). Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin-diabetic rats. J Pharmacol Exp Ther 296: 252-259.
9. Barrera G, Pizzimenti S, Dianzani MU (2004). 4-hydroxynonenal and regulation of cell cycle: effects on the pRb/E2F pathway. Free Radic Biol Med 37: 597-606.
10. Barrera G, Pizzimenti S, Serra A, Feretti C, Fazio VM, Saglio G et al. (1996). 4-hydroxynonenal specifically inhibits c-myb but does not affect c-fos expressions in HL-60 cells. Biochem Biophys Res Commun 227: 589-593.
11. Baynes JW, Thorpe SR (2000). Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28: 1708-1716.
12. Biasi F, Vizio B, Mascia C, Gaia E, Zarkovic N, Chiarpotto E et al. (2006). c-Jun N-terminal kinase upregulation as a key event in the proapoptotic interaction between transforming growth factor-beta1 and 4-hydroxynonenal in colon mucosa. Free Radic Biol Med 41: 443-454.
13. Boldogh I, Bacsi A, Choudhury BK, Dharajiya N, Alam R, Hazra TK et al. (2005). ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation. J Clin Invest 115: 2169-2179.
14. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K et al. (2004). Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24: 32-40.
15. Borovic S, Rabuzin F, Waeg G, Zarkovic N (2006). Enzyme-linked immunosorbent assay for 4-HNE-histidine conjugates. Free Radic Res 40: 809-820.
16. Brooke I CJ, Cocker J, Groves J (1997). Phenylhydrazine Sudbury, Suffolk, HSE Books, Risk Assessment Document EH 72/1.
17. Brown BE, Dean RT, Davies MJ (2005). Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 48: 361-369.
18. Brown BE, Mahroof FM, Cook NL, van Reyk DM, Davies MJ (2006). Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells fromglycolaldehyde-modified low-density lipoproteins. Diabetologia 49: 775-783.
19. Brown DR (2005). Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol 43: 229-243.
20. Brown MS, Goldstein JL (1983). Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52: 223-261.
21. Burcham PC, Kaminskas LM, Fontaine FR, Petersen DR, Pyke SM (2002). Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 181-182: 229-236.
22. Burcham PC, Kerr PG, Fontaine F (2000). The antihypertensive hydralazine is an efficient scavenger of acrolein. Redox Rep 5: 47-49.
23. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC (1997). Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 23: 361-366.
24. Cahuana GM, Tejedo JR, Jimenez J, Ramirez R, Sobrino F, Bedoya FJ (2003). Involvement of advanced lipooxidation end products (ALEs) and protein oxidation in the apoptotic actions of nitric oxide in insulin secreting RINm5F cells. Biochem Pharmacol 66: 1963-1971.
25. Cantero AV, Portero-Otin M, Ayala V, Auge N, Sanson M, Elbaz M et al. (2007). Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-\{beta\}: implications for diabetic atherosclerosis. FASEB J 21: 1-11.
26. Carini M, Aldini G, Facino RM (2004). Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins. Mass Spectrom Rev 23: 281-305.
27. Carluccio F, Siems W, Stefanelli G, Sommerburg O, Grune T, Riedel E et al. (2002). Homocysteine in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde. Clin Nephrol 58 (Suppl 1): S26-S30.
28. Castello L, Marengo B, Nitti M, Froio T, Domenicotti C, Biasi F et al. (2005). 4-Hydroxynonenal signalling to apoptosis in isolated rat hepatocytes: the role of PKC-delta. Biochim Biophys Acta 1737: 83-93.
29. Castro SM, Guerrero-Plata A, Suarez-Real G, Adegboyega PA, Colasurdo GN, Khan AM et al. (2006). Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation. Am J Respir Crit Care Med 174: 1361-1369.
30. Chan WH, Wu HJ, Shiao NH (2007). Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J Cell Biochem 100: 1056-1069.
31. Chen AS, Taguchi T, Sugiura M, Wakasugi Y, Kamei A, Wang MW et al. (2004). Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm Metab Res 36: 183-187.
32. Chen JJ, Bertrand H, Yu BP (1995). Inhibition of adenine nucleotide translocator by lipid peroxidation products. Free Radic Biol Med 19: 583-590.
33. Chen ZH, Saito Y, Yoshida Y, Sekine A, Noguchi N, Niki E (2005). 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem 280: 41921-41927.
34. Cheng JZ, Singhal SS, Sharma A, Saini M, Yang Y, Awasthi S et al. (2001). Transfection of mGSTA4 in HL-60 cells protects against 4-hydroxynonenal-induced apoptosis by inhibiting JNK-mediated signaling. Arch Biochem Biophys 392: 197-207.
35. Chisolm GM, Steinberg D (2000). The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28: 1815-1826.
36. Choudhary S, Zhang W, Zhou F, Campbell GA, Chan LL, Thompson EB et al. (2002). Cellular lipid peroxidation end-products induce apoptosis in human lens epithelial cells. Free Radic Biol Med 32: 360-369.
37. Chowdhury PK, Halder M, Choudhury PK, Kraus GA, Desai MJ, Armstrong DW et al. (2004). Generation of fluorescent adducts of malondialdehyde and amino acids: toward an understanding of lipofuscin. Photochem Photobiol 79: 21-25.
38. Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, Serraino I, Britti D et al. (2002). Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol 135: 496-510.
39. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A (2003). Protein carbonylation in human diseases. Trends Mol Med 9: 169-176.
40. de Arriba SG, Krugel U, Regenthal R, Vissiennon Z, Verdaguer E, Lewerenz A et al. (2006). Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radic Biol Med 40: 779-790.
41. de Villiers WJ, Song Z, Nasser MS, Deaciuc IV, McClain CJ (2007). 4-Hydroxynonenal-induced apoptosis in rat hepatic stellate cells: mechanistic approach. J Gastroenterol Hepatol 22: 414-422.
42. deWinther MP, Kanters E, Kraal G, Hofker MH (2005). Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 25: 904-914.
43. Dianzani MU (1989). Lipid peroxidation and cancer: a critical reconsideration. Tumori 75: 351-357.
44. Donath B, Fischer C, Page S, Prebeck S, Jilg N, Weber M (2002). Chlamydia pneumoniae activates IKK/I kappa B-mediated signaling, which is inhibited by 4-HNE and following primary exposure. Atherosclerosis 165: 79-88.
45. Endo N, Nishiyama K, Otsuka A, Kanouchi H, Taga M, Oka T (2006). Antioxidant activity of vitamin B6 delays homocysteine-induced atherosclerosis in rats. Br J Nutr 95: 1088-1093.
46. Escargueil-Blanc I, Salvayre R, Vacaresse N, Jurgens G, Darblade B, Arnal JF et al. (2001). Mildly oxidized LDL induces activation of platelet-derived growth factor beta-receptor pathway. Circulation 104: 1814-1821.
47. Esterbauer H (1993). Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 57: 779S-785S; discussion 785S-786S.
48. Esterbauer H, Dieber-Rotheneder M, Waeg G, Striegl G, Jurgens G (1990). Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol 3: 77-92.
49. Esterbauer H, Schaur RJ, Zollner H (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128.
50. Ferrington DA, Kapphahn RJ (2004). Catalytic site-specific inhibition of the 20S proteasome by 4-hydroxynonenal. FEBS Lett 578: 217-223.
51. Fraley AE, Tsimikas S (2006). Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 17: 502-509.
52. Fredrikson GN, Berglund G, Alm R, Nilsson JA, Shah PK, Nilsson J (2006). Identification of autoantibodies in human plasma recognizing an apoB-100 LDL receptor binding site peptide. J Lipid Res 47: 2049-2054.
53. Friguet B (2006). Oxidized protein degradation and repair in ageing and oxidative stress. FEBS Lett 580: 2910-2916.
54. Fu AL, Dong ZH, Sun MJ (2006). Protective effect of N-acetyl-L- cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res 1109: 201-206.
55. Fukunaga M, Miyata S, Higo S, Hamada Y, Ueyama S, Kasuga M (2005). Methylglyoxal induces apoptosis through oxidative stress-mediated activation of p38 mitogen-activated protein kinase in rat Schwann cells. Ann NY Acad Sci 1043: 151-157.
56. Grimble RF (1997). Effect of antioxidative vitamins on immune function with clinical applications. Int J Vitam Nutr Res 67: 312-320.
57. Grimsrud PA, Picklo Sr MJ, Griffin TJ, Bernlohr DA (2007). Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell Proteomics.
58. Grune T, Davies KJ (2003). The proteasomal system and HNE-modified proteins. Mol Aspects Med 24: 195-204.
59. Grune T, Michel P, Sitte N, Eggert W, Albrecht-Nebe H, Esterbauer H et al. (1997). Increased levels of 4-hydroxynonenal modified proteins in plasma of children with autoimmune diseases. Free Radic Biol Med 23: 357-360.
60. Guiotto A, Calderan A, Ruzza P, Borin G (2005). Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 12: 2293-2315.
61. Hajjar DP, Haberland ME (1997). Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 272: 22975-22978.
62. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL et al. (1999). The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 44: 579-587.
63. Hayek T, Attias J, Smith J, Breslow JL, Keidar S (1998). Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 31: 540-544.
64. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, Abbot NJ (1997). Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett 238: 135-138.
65. Hoppe G, O'Neil J, Hoff HF (1994). Inactivation of lysosomal proteases by oxidized low density lipoprotein is partially responsible for its poor degradation by mouse peritoneal macrophages. J Clin Invest 94: 1506-1512.
66. Hubatsch I, Ridderstrom M, Mannervik D (1998). Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. Biochem J 330: 175-179.
67. Imai H, Graham DI, Masayasu H, Macrae IM (2003). Antioxidant ebselen reduces oxidative damage in fical cerebral ischemia. Free Rad Biol Med 34: 56-63.
68. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B et al. (2005). The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 67: 2288-2294.
69. Jan CR, Chen CH, Wang SC, Kuo SY (2005). Effect of methylglyoxal on intracellular calcium levels and viability in renal tubular cells. Cell Signal 17: 847-855.
70. Je JH, Lee JY, Jung KJ, Sung B, Go EK, Yu BP et al. (2004). NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett 566: 183-189.
71. Jedidi I, Therond P, Zarev S, Cosson C, Couturier M, Massot C et al. (2003). Paradoxical protective effect of aminoguanidine toward low-density lipoprotein oxidation: inhibition of apolipoprotein B fragmentation without preventing its carbonylation. Mechanism of action of aminoguanidine. Biochemistry 42: 11356-11365.
72. Jenner P (2003). Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3): S26-S36; discussion S36-28.
73. Jurgens G, Ashy A, Esterbauer H (1990). Detection of new epitopes formed upon oxidation of LDL, lipoprotein (a) and VLDL. Use of an antiserum against 4-HNE-modified LDL. Biochem J 265: 605-608.
74. Jurgens G, Hoff HF, Chisolm III GM, Esterbauer H (1987). Modification of human serum low density lipoprotein by oxidation - characterization and pathophysiological implications. Chem Phys Lipids 45: 315-336.
75. Jürgens G, Lang J, Esterbauer H (1986). Modification of human LDL by the lipid peroxydation product 4-hydroxynonenal. Biochim Biophys Acta 875: 103-114.
76. Kaminskas LM, Pyke SM, Burcham PC (2004). Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice. J Pharmacol Exp Ther 310: 1003-1010.
77. Kang Z, Li H, Li G, Yin D (2006). Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products. Amino Acids 30: 55-61.
78. Kapphahn RJ, Bigelow EJ, Ferrington DA (2007). Age-dependent inhibition of proteasome chymotrypsin-like activity in the retina. Exp Eye Res 84: 646-654.
79. Kono H, Arteel GE, Rusyn I, Sies H, Thurman RG (2001). Ebselen prevents early alcohol-induced liver injury in rats. Free Rad Biol Med 30: 403-411.
80. Kreuzer T, Grube R, Wutte A, Zarcovic N, Schaur RJ (1998). 4-Hydroxynonenal modifies the effects of serum growth factors on the expression of the c-fos proto-oncogene and the proliferation of HeLa carcinoma cells. Free Radic Biol Med 25: 42-49.
81. Kreuzer T, Zarcovic N, Grube R, Schaur RJ (1997). Inhibition of HeLa cell proliferation by 4-hydroxynonenal is associated with enhanced expression of the c-fos oncogene. Cancer Biother Radiopharm 12: 131-136.
82. Kristal BS, Park BK, Yu BP (1996). 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem 271: 6033-6038.
83. Kruman II, Mattson MP (1999). Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. J Neurochem 72: 529-540.
84. Lee JY, Je JH, Kim DH, Chung SW, Zou Y, Kim ND et al. (2004). Induction of endothelial apoptosis by 4-hydroxyhexenal. Eur J Biochem 271: 1339-1347.
85. Lee JY, Jung GY, Heo HJ, Yun MR, Park JY, Bae SS et al. (2006). 4-Hydroxynonenal induces vascular smooth muscle cell apoptosis through mitochondrial generation of reactive oxygen species. Toxicol Lett 166: 212-221.
86. Leonarduzzi G, Chiarpotto E, Biasi F, Poli G (2005). 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res 49: 1044-1049.
87. Leonarduzzi G, Robbesyn F, Poli G (2004). Signaling kinases modulated by 4-hydroxynonenal. Free Radic Biol Med 37: 1694-1702.
88. Liu W, Akhand AA, Kato M, Yokoyama I, Miyata T, Kurokawa K et al. (1999). 4-hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition. J Cell Sci 112: 2409-2417.
89. Loguercio C, Federico A (2003). Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 34: 1-10.
90. Lovell MA, Markesbery WR (2006). Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Curr Alzheimer Res 3: 359-364.
91. Lyons TJ, Silvestri G, Dunn JA, Dyer DG, Baynes JW (1991). Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes 40: 1010-1015.
92. Makita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara H, Koike T (1996). The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrol Dial Transplant 11 (Suppl 5): 31-33.
93. Marques C, Pereira P, Taylor A, Liang JN, Reddy VN, Szweda LI et al. (2004). Ubiquitin-dependent lysosomal degradation of the HNE-modified proteins in lens epithelial cells. FASEB J 18: 1424-1426.
94. Marsili S, Salganik RI, Albright CD, Freel CD, Johnsen S, Peiffer RL et al. (2004). Cataract formation in a strain of rats selected for high oxidative stress. Exp Eye Res 79: 595-612.
95. Mattson MP, Chan SL (2003). Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34: 385-397.
96. McEwen JE, Zimniak P, Mehta JL, Reis RJ (2005). Molecular pathology of aging and its implications for senescent coronary atherosclerosis. Curr Opin Cardiol 20: 399-406.
97. Miyata T, Ueda Y, Asahi K, Izuhara Y, Inagi R, Saito A et al. (2000). Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2- isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11: 1719-1725.
98. Montan S (2004). Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol 16: 111-115.
99. Morgan PE, Sturgess AD, Davies MJ (2005). Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52: 2069-2079.
100. Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M (2006). Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum 54: 271-281.
101. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA et al. (1996). Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98: 1465-1470.
102. Nadkarni DV, Sayre LM (1995). Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 8: 284-291.
103. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y et al. (2003). Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14: 1212-1222.
104. Nitti M, Domenicotti C, d'Abramo C, Assereto S, Cottalasso D, Melloni E et al. (2002). Activation of PKC-beta isoforms mediates HNE-induced MCP-1 release by macrophages. Biochem Biophys Res Commun 294: 547-552.
105. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Ushida K (1999). 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274: 23787-23793.
106. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW (2000). Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 275: 21177-21184.
107. Page S, Fischer C, Baumgartner B, Haas M, Kreusel U, Loidl G et al. (1999). 4-Hydroxynonenal prevents NF-kappaB activation and tumor necrosis factor expression by inhibiting IkappaB phosphorylation and subsequent proteolysis. J Biol Chem 274: 11611-11618.
108. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW et al. (1989). Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86: 1372-1376.
109. Petersen DR, Doorn JA (2004). Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 37: 937-945.
110. Peyroux J, Sternberg M (2006). Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 54: 405-419.
111. Pierre F, Peiro G, Tache S, Cross AJ, Bingham SA, Gasc N et al. (2006). New marker of colon cancer risk associated with heme intake: 1,4-dihydroxynonane mercapturic acid. Cancer Epidemiol Biomarkers Prev 15: 2274-2279.
112. Pierre F, Tache S, Gueraud F, Rerole AL, Jourdan ML, Petit C (2007). Apc mutation induces resistance of colonic cells to lipoperoxide-triggered apoptosis induced by faecal water from haem-fed rats. Carcinogenesis 28: 321-327.
113. Poli G, Schaur RJ (2000). 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 50: 315-321.
114. Portero-Otin M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R et al. (2002). Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes 51: 1535-1542.
115. Price DL, Rhett PM, Thorpe SR, Baynes JW (2001). Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276: 48967-48972.
116. Pugazhenthi S, Phansalkar K, Audesirk G, West A, Cabell L (2006). Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic Biol Med 40: 21-34.
117. Ramasamy R, Yan SF, Schmidt AM (2006). Methylglyoxal comes of AGE. Cell 124: 258-260.
118. Raza H, John A (2006). 4-hydroxynonenal induces mitochondrial oxidative stress, apoptosis and expression of glutathione S-transferase A4-4 and cytochrome P450 2E1 in PC12 cells. Toxicol Appl Pharmacol 216: 309-318.
119. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J, Van Obberghen E (2006). Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 55: 1289-1299.
120. Robbesyn F, Garcia V, Auge N, Vieira O, Frisach MF, Salvayre R et al. (2003). HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 17: 743-745.
121. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME (2000). Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 374: 325-333.
122. Roff M, Thompson J, Rodriguez MS, Jacque JM, Baleux F, Arenzana-Seisdedos F et al. (1996). Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem 271: 7844-7850.
123. Rohn TT, Nelson LK, Waeg G, Quinn MT (1998). U-101033E (2,4-diaminopyrrolopyrimidine), a potent inhibitor of membrane lipid peroxidation as assessed by the production of 4-hydroxynonenal, malondialdehyde, and 4-hydroxynonenal-protein adducts. Biochem Pharmacol 56: 1371-1379.
124. Ross R (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809.
125. Satoh K, Yamada S, Koike Y, Igarashi Y, Toyokuni S, Kumano T et al. (1999). A 1-hour enzyme-linked immunosorbent assay for quantitation of acrolein- and hydroxynonenal-modified proteins by epitope-bound casein matrix method. Anal Biochem 270: 323-328.
126. Sayre LM, Arora PK, Iyer RS, Salomon RG (1993). Pyrrole formation from 4-hydroxynonenal and primary amines. Chem Res Toxicol 6: 19-22.
127. Sayre LM, Lin D, Yuan Q, Zhu X, Tang X (2006). Protein adducts generated from products of lipid oxidation: focus on HNE and one. Drug Metab Rev 38: 651-675.
128. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997). 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68: 2092-2097.
129. Schaur RJ (2003). Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol Aspects Med 24: 149-159.
130. Shah R, Raska Jr K, Tiku ML (2005). The presence of molecular markers of in vivo lipid peroxidation in osteoarthritic cartilage: a pathogenic role in osteoarthritis. Arthritis Rheum 52: 2799-2807.
131. Shi Q, Vaillancourt F, Cote V, Fahmi H, Lavigne P, Afif H et al. (2006). Alterations of metabolic activity in human osteoarthritic osteoblasts by lipid peroxidation end product 4-hydroxynonenal. Arthritis Res Ther 8: R159.
132. Shibamoto T (2006). Analytical methods for trace levels of reactive carbonyl compounds formed in lipid peroxidation systems. J Pharm Biomed Anal 41: 12-25.
133. Shringarpure R, Grune T, Mehlhase J, Davies KJ (2003). Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 278: 311-318.
134. Shringarpure R, Grune T, Sitte N, Davies KJ (2000). 4-Hydroxynonenal- modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell Mol Life Sci 57: 1802-1809.
135. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W et al. (2002). Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol 58 (Suppl 1): S12-S19.
136. Siow RC, Ishii T, Mann GE (2007). Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. Redox Rep 12: 11-15.
137. Sitte N, Merker K, Von Zglinicki T, Grune T, Davies KJ (2000). Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I - effects of proliferative senescence. FASEB J 14: 2495-2502.
138. Smit AJ, Lutgers HL (2004). The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11: 2767-2784.
139. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N et al. (1998). Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 46: 731-735.
140. Steinberg D (1997). Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272: 20963-20966.
141. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989). Beyond cholesterol. Modifications of LDL that increase its atherogenicity. N Engl J Med 320: 915-924.
142. Steinbrecher UP (1999). Receptors for oxidized low density lipoprotein. Biochim Biophys Acta 1436: 279-298.
143. Suarna C, Wu BJ, Choy K, Mori T, Croft K, Cynshi O et al. (2006). Protective effect of vitamin E supplements on experimental atherosclerosis is modest and depends on preexisting vitamin E deficiency. Free Radic Biol Med 41: 722-730.
144. Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Negre-Salvayre A (1997). HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 17: 2158-2166.
145. Suc I, Meilhac O, Lajoie-Mazenc I, Vandaele J, Jurgens G, Salvayre R (1998). Activation of EGF receptor by oxidized LDL. FASEB J 12: 665-671.
146. Tang SC, Arumugam TV, Cutler RG, Jo DG, Magnus T, Chan SL et al. (2007). Neuroprotective actions of a histidine analogue in models of ischemic stroke. J Neurochem 101: 729-736.
147. Thomas MC, Forbes JM, MacIsaac R, Jerums G, Cooper ME (2005). Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Ann NY Acad Sci 1043: 644-654.
148. Thornalley PJ (2003). Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419: 31-40.
149. Thornalley PJ, Langborg A, Minhas HS (1999). Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344 (Part 1): 109-116.
150. Thornalley PJ, Yurek-George A, Argirov OK (2000). Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60: 55-65.
151. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J et al. (1998). Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 18: 369-378.
152. Tsimikas S (2006). Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 8: 55-61.
153. Tsuneyama K, Harada K, Kono N, Sasaki M, Saito T, Gershwin ME et al. (2002). Damaged interlobular bile ducts in primary biliary cirrhosis show reduced expression of glutathione-S-transferase-pi and aberrant expression of 4-hydroxynonenal. J Hepatol 37: 176-183.
154. Uchida K (2000). Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28: 1685-1696.
155. Uchida K (2003). 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42: 318-343.
156. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S, Stadtman ER (1995). Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys 324: 241-248.
157. Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E (1998). Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 273: 16058-16066.
158. Vacaresse N, Vieira O, Robbesyn F, Jurgens G, Salvayre R, Negre-Salvayre A (2001). Phenolic antioxidants trolex and caffeic acid modulate the oxidized LDL-induced EGF-receptor activation. Br J Pharmacol 132: 1777-1788.
159. Valacchi G, Pagnin E, Phung A, Nardini M, Schock BC, Cross CE et al. (2005). Inhibition of NFkappaB activation and IL-8 expression in human bronchial epithelial cells by acrolein. Antioxid Redox Signal 7: 25-31.
160. Valentovic M, Terneus M, Harmon RC, Carpenter AB (2004). S-Adenosylmethionine (SAMe) attenuates acetaminophen hepatotoxicity in C57BL/6 mice. Toxicol Lett 154: 165-174.
161. Van Kuijk FJ, Holte LL, Dratz EA (1990). 4-Hydroxyhexenal: a lipid peroxidation product derived from oxidized docosahexaenoic acid. Biochim Biophys Acta 1043: 116-118.
162. Vieira O, Escargueil-Blanc I, Jurgens G, Borner C, Almeida L, Salvayre R et al. (2000). Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis. FASEB J 14: 532-542.
163. Vindis C, Escargueil-Blanc I, Elbaz M, Marcheix B, Grazide MH, Uchida K et al. (2006). Desensitization of platelet-derived growth factor receptor-beta by oxidized lipids in vascular cells and atherosclerotic lesions: prevention by aldehyde scavengers. Circ Res 98: 785-792.
164. Virlos I, Mazzon E, Serraino I, Di Paola R, Genovese T, Britti D et al. (2003). Pyrrolidine dithiocarbamate reduces the severity of cerulein-induced murine acute pancreatitis. Shock 20: 544-550.
165. Voss P, Siems W (2006). Clinical oxidation parameters of aging. Free Radic Res 40: 1339-1349.
166. Voziyan PA, Hudson BG (2005). Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 62: 1671-1681.
167. Waeg G, Dimsity G, Esterbauer H (1996). Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins. Free Radic Res 25: 149-159.
168. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S et
169. Weber LW, Boll M, Stampfl A (2003). Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 33: 105-136.
170. Whitnall M, Richardson DR (2006). Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 13: 186-197.
171. Xu G, Liu Y, Sayre LM (2000). Polyclonal antibodies to a fluorescent 4-hydroxy-2-nonenal (HNE)-derived lysine-lysine cross-link: characterization and application to HNE-treated protein and in vitro oxidized low-density lipoprotein. Chem Res Toxicol 13: 406-413.
172. Yang Y, Sharma R, Sharma A, Awasthi S, Awasthi YC (2003). Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol 50: 319-336.
173. Yao HW, Zhu JP, Zhao MH, Lu Y (2006). Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration 73: 236-242.
174. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996). Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93: 2696-2701.
175. Yu PH, Zuo DM (1997). Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 40: 1243-1250.
176. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B et al. (2006). Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55: 2180-2191.
177. Zarkovic N (2003). 4-hydroxynonenal as a bioactive marker of pathophysiological processes. Mol Aspects Med 24: 281-291.
178. Zarkovic N, Ilic Z, Jurin M, Schaur RJ, Puhl H, Esterbauer H (1993). Stimulation of HeLa cell growth by physiological concentrations of 4-hydroxynonenal. Cell Biochem Funct 11: 279-286.
179. Zhang H, Court N, Forman HJ (2007). Submicromolar concentrations of 4-hydroxynonenal induce glutamate cysteine ligase expression in HBE1 cells. Redox Rep 12: 101-106.